The PREFER Recommendations
Supporting the development of guidelines for structured patient input into decision-making for the pharmaceutical industry, regulatory authorities, health technology assessment bodies and reimbursement agencies!
.png)
PREFER Expert Network
The PREFER EXPERT NETWORK is a voluntary network of pharmaceutical companies, academic institutions, consultants, and patient representatives devoted to promoting the development and adoption of patient preferences in decision-making about medical products.
Developing recommendations
We are developing evidence-based recommendations to guide industry, regulatory authorities, HTA bodies, reimbursement agencies, and health care professionals. We start with work to assess methodologies. After that, we test them in clinical case studies. This work will be the basis for the recommendations we make.
Together with stakeholders
The PREFER project starts and ends with stakeholders. Their input is crucial for this project to succeed. The project includes partners representing patient organisations and clinical research, HTA bodies and industry. We also have stakeholder advisory groups for patients, regulators, HTA-bodies and payers. With them on board, we trust our results will be relevant and useful.
Through clinical case studies
Our researchers will test different methods for preference elicitation in clinical case studies. We will evaluate what patients think is relevant about their disease and its impact. We will look at which treatment options they prefer and their willingness to accept trade-offs between benefits and risks of their treatment. These methods will be evaluated at different decision points in the drug development process.
FINDING OUT WHAT PATIENTS PREFER
Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five year public-private research project where academic researchers, HTA, patient organisations, and the pharmaceutical industry work together to find out when, and how patients’ treatment preferences can be used in medical product development.
We are looking forward to sharing our findings with you!
Mats G. Hansson, Uppsala University, Coordinator
Conny Berlin, Novartis, Project Leader
Innovative Medicines Initiative
PREFER is funded by the Innovative Medicines Initiative (IMI): a part of the EU Horizon 2020 Programme.
European Union
The academic research in PREFER is funded by Horizon 2020: the EU Framework Programme for Research and Innovation.
EFPIA
The pharmaceutical industry contributes equally to the PREFER project. Industry input to the IMI programme is organised by EFPIA.
